---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-276662"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:11:11.743732+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Alaunos receives Nasdaq delisting notice; Q3 net loss $8.5M; exploring strategic alternatives

## Summary
- Nasdaq determined to delist TCRT because bid price was below $0.10 for 10 consecutive days; suspension effective Nov 17, 2023.
- Company intends to appeal to a Nasdaq Hearings Panel; trading stays pending appeal.
- Q3 2023 net loss $8.5M ($0.04 per share); revenue $0 vs $2.9M a year ago.
- Cash and equivalents $11.9M; cost-savings expected to extend runway into Q2 2024.
- TCR-T Phase 1/2 trial showed 87% disease control rate in 8 patients; company halted further development.

## SEC filing metadata
- accession: 0001193125-23-276662
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/0001193125-23-276662-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/d349273d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-276662
- JSON: https://secwatch.observer/filing/0001193125-23-276662.json
- Plain text: https://secwatch.observer/filing/0001193125-23-276662.txt

## Key facts
- Earnings Releases
  Alaunos Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: net income Net loss was $8.5 million, or $(0.04) per share.
  - Period: the third quarter ended September 30, 2023
  - Net income: Net loss was $8.5 million, or $(0.04) per share
  - Result: reported results
  source text: On November 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial condition and results of operations for the three months ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/0001193125-23-276662-index.htm
- Listing & Compliance Notices
  Alaunos Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(A)(iii)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: minimum bid price
  - Rules: 5450(a)(1), 5810(c)(3)(A), 5810(c)(3)(A)(iii)
  source text: November 8, 2023, the Company received a Staff Delisting Determination letter (the “Delisting Determination”) from the Staff notifying the Company that, because the closing bid price for the Common Stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of the Common Stock on Nasdaq pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), effective November 17, 2023, and file a Form 25-NSE with the Securities and Exchange Commission (the “SEC”) to remove the Common Stock from listing and registration under th
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523276662/0001193125-23-276662-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.